Filing Details

Accession Number:
0001415889-23-011986
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-09 18:00:15
Reporting Period:
2023-08-07
Accepted Time:
2023-08-09 18:00:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE Pharmaceutical Preparations (2834) 831377888
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1869248 T Benjamin Dake C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-07 2,412 $1.74 3,703 No 4 M Direct
Common Stock Acquisiton 2023-08-07 7,871 $2.14 11,574 No 4 M Direct
Common Stock Disposition 2023-08-07 9,742 $15.48 1,832 No 4 S Direct
Common Stock Disposition 2023-08-07 541 $16.25 1,291 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-08-07 905 $0.00 905 $1.74
Common Stock Stock Option (Right to Buy) Disposition 2023-08-07 1,507 $0.00 1,507 $1.74
Common Stock Stock Option (Right to Buy) Disposition 2023-08-07 1,018 $0.00 1,018 $2.14
Common Stock Stock Option (Right to Buy) Disposition 2023-08-07 6,853 $0.00 6,853 $2.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,528 2030-09-03 No 4 M Direct
18,082 2030-09-03 No 4 M Direct
20,368 2031-04-01 No 4 M Direct
150,756 2031-04-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.17 to $16.17, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.175 to $16.470, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of theshares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  5. A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  6. A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.
  7. A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.